&nbsp;

E.1.50-CAR-TReferralWorksheet.pdf

Dec 1969

Regimen

EC+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Regimen

NIVL+IPIL

Cancer Type:

Skin,

Melanoma

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Regimen

NIVL

Cancer Type:

Skin,

Melanoma

Intent: Adjuvant

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab - (Neo)adjuvant Resectable Macroscopic Stage III Melanoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Drug

niraparib / abiraterone

Other Name(s): Akeega™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Dec 1969

Regimen

NIVL+IPIL

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

Drugs Used:

nivolumab,

ipilimumab

Quick Link(s):

Regimen Monograph

Jan 2026

Regimen

NIVL(MNT)

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

New Drug Funding Program

Nivolumab plus Ipilimumab – Previously Untreated Unresectable or Advanced Hepatocellular Carcinoma

Drugs Used:

nivolumab

Quick Link(s):

Regimen Monograph

Jan 2026

Document

Errata-Tables

New

Nov 2025

Document

Errata-Tables-FR

New

Nov 2025

Document

Errata-Figures

New

Nov 2025

Document

Errata2

New

Nov 2025

Document